News
-
Expanding on a partnership established in 2023, and following the closure of Bespak’s OINDP development facilities in North Carolina, CDMO Bespak and CRO OzUK say that they will now offer continuity of low global warming… Read more . . .
-
Tiziana Life Sciences announced that a Phase 2a clinical of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS) has been expanded to include additional trial sites at Yale, Johns Hopkins, Cornell, Thomas… Read more . . .
-
According to Iliad Biotechnologies, the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has granted Innovation Passport designation to Iliad’s BPZE1 intranasal pertussis vaccine. BPZE1, which is in Phase 2 development, has previously received Fast Track designation… Read more . . .
-
Orbia Fluor & Energy Materials (formerly Koura Global) has announced plans for a new manufacturing facility for its Zephex HFA 152a LGWP MDI propellant, saying that the plant will produce significantly more 152a than the… Read more . . .
-
According to AlveoGene, the FDA has granted orphan drug designation to the company’s AVG-002 inhaled gene therapy for the treatment of neonatal surfactant protein B deficiency. AVG-002 also recently received rare pediatric disease designation for that… Read more . . .
-
CDMO Hovione has announced the completion of expansion projects at its facilities in East Windsor, NJ, USA and Ringaskiddy, Cork, Ireland that its says will provide a significant increase in the company’s spray drying capacity and will… Read more . . .
-
According to Satsuma Pharmaceuticals and its parent company Shin Nippon Biomedical Laboratories, the FDA has accepted the company’s resubmitted NDA for STS101 dihydroergotamine nasal powder for the treatment of migraine and has set a PDUFA… Read more . . .
-
Blue Lake Biotechnology and CyanVac reported that a Phase 2a clinical trial of their CVXGA intranasal vaccine against SARS-CoV-2 demonstrated that participants who received CVXGA had a 78% lower risk of symptomatic infection one month… Read more . . .
-
Virpax Pharmaceuticals announced the extension of a research and development agreement with an institute of the National Institutes of Health (NIH) related to the company’s NES100 enkephalin nasal spray for the treatment of acute and… Read more . . .
-
The ALS Association, which supports research on amyotrophic lateral sclerosis, has awarded a grant to Tiziana Life Sciences to support a clinical trial of intranasal foralumab in 20 patients with ALS at Massachusetts General Hospital,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK